Moleculin Biotech Liabilities 2024

Moleculin Biotech Aktienanalyse

What does Moleculin Biotech do?

Moleculin Biotech Inc is a biopharmaceutical company based in Houston, Texas, that focuses on the development of innovative cancer therapies. The company was founded in 2015 and has since made significant progress in the research and development of drugs for the treatment of cancer. The company follows an innovative business model consisting of two main divisions: research and development, as well as distribution. Moleculin Biotech focuses on identifying compounds that target specific types and stages of cancer in order to enable personalized cancer treatment. The company currently has several projects in the pipeline, each with the potential to change the way cancer is treated. In the research department, Moleculin Biotech focuses on identifying compounds that target cancer types that have been difficult to treat. The company is dedicated to developing effective drugs that can inhibit cell division in certain types of cancer and stop their growth. The critical goal is to develop medications that selectively attack cancer cells without affecting healthy cells. The distribution department of Moleculin Biotech is responsible for marketing and distributing the developed drugs. The company has a well-established network of distribution partners and agencies that help with the introduction of new products. Moleculin Biotech aims to distribute its products worldwide and continuously expand its patient base. One of Moleculin Biotech's key products is the compound WP1122. This molecule is a prodrug capable of selectively accumulating and acting in cancer cells. As a result, it can be used in combination with other cancer therapies to increase treatment efficacy. The company has already demonstrated the potential of WP1122 in clinical trials and is currently working on its market launch. Another significant product of Moleculin Biotech is Annamycin. This is a chemotherapeutic specifically developed for the treatment of leukemia. The medication has already been tested in clinical trials and proven to be effective. Annamycin has the potential to dramatically change and improve the treatment of leukemia. In addition to these two products, Moleculin Biotech also has MSP-2017 in its portfolio. This anti-tumor drug specifically targets pancreatic cancer and has the potential to increase the survival rate of patients in advanced stages of the disease. MSP-2017 is currently still in the development phase and is expected to enter the market in the coming years. Overall, Moleculin Biotech is a promising company focusing on the development of innovative cancer therapies. The company has the potential to fundamentally change cancer treatment and save the lives of millions of people worldwide. The company is committed to intensifying its research and development activities and continuously expanding its product pipeline. Moleculin Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Moleculin Biotech's Liabilities

Moleculin Biotech's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Moleculin Biotech's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Moleculin Biotech's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Moleculin Biotech's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Moleculin Biotech’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Moleculin Biotech stock

What is the level of liabilities of Moleculin Biotech this year?

Moleculin Biotech has a debt balance of 12.14 M USD this year.

What were the liabilities of Moleculin Biotech compared to the previous year?

The liabilities of Moleculin Biotech have increased by 132.15% increased compared to the previous year.

What are the consequences of high debt for investors of Moleculin Biotech?

High liabilities can pose a risk for investors of Moleculin Biotech, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Moleculin Biotech?

Low liabilities mean that Moleculin Biotech has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Moleculin Biotech affect the company?

An increase in liabilities of Moleculin Biotech can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Moleculin Biotech affect the company?

A decrease in the liabilities of Moleculin Biotech can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Moleculin Biotech?

Some factors that can influence the liabilities of Moleculin Biotech include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Moleculin Biotech so important for investors?

The liabilities of Moleculin Biotech are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Moleculin Biotech take to modify the liabilities?

To change its liabilities, Moleculin Biotech can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Moleculin Biotech pay?

Over the past 12 months, Moleculin Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Moleculin Biotech is expected to pay a dividend of 0 USD.

What is the dividend yield of Moleculin Biotech?

The current dividend yield of Moleculin Biotech is .

When does Moleculin Biotech pay dividends?

Moleculin Biotech pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Moleculin Biotech?

Moleculin Biotech paid dividends every year for the past 0 years.

What is the dividend of Moleculin Biotech?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Moleculin Biotech located?

Moleculin Biotech is assigned to the 'Health' sector.

Wann musste ich die Aktien von Moleculin Biotech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Moleculin Biotech from 8/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/1/2024.

When did Moleculin Biotech pay the last dividend?

The last dividend was paid out on 8/1/2024.

What was the dividend of Moleculin Biotech in the year 2023?

In the year 2023, Moleculin Biotech distributed 0 USD as dividends.

In which currency does Moleculin Biotech pay out the dividend?

The dividends of Moleculin Biotech are distributed in USD.